A Review of Current and Emerging Treatment Options for Myelodysplastic Syndromes

Download All
In this comprehensive program centered on an in-person and online live CCO symposium at ASH 2021, experts discuss recent developments in the management of myelodysplastic syndromes. Review their insights in an on-demand webcast and downloadable slides from the symposium.
Michael J. Savona, MD
Program Director
Jacqueline S. Garcia, MD
Michael J. Savona, MD
Amer Zeidan, MBBS, MPH

Downloadable Slidesets

Download these slides from a live webinar for the latest evidence on treatment approaches and managing anemia in lower-risk MDS

Michael J. Savona, MD Released: December 10, 2021

Download these slides from a live webinar for expert guidance on treatment approaches for higher-risk MDS and strategies for managing relapsed/refractory MDS

Jacqueline S. Garcia, MD Released: December 10, 2021

Download these slides from a live webinar for updates on immuno-oncology therapeutic strategies in MDS

Amer Zeidan, MBBS, MPH Released: December 10, 2021

Download this summary slideset from a live webinar for the latest evidence on treatment approaches for lower-risk, higher-risk, and relapsed/refractory MDS.

Michael J. Savona, MD
Program Director
Jacqueline S. Garcia, MD Amer Zeidan, MBBS, MPH
Released: December 23, 2021

On-Demand Webcast

Learn about current and emerging treatment options for myelodysplastic syndromes from expert faculty in this webcast from a live CCO symposium.

Michael J. Savona, MD
Program Director
Jacqueline S. Garcia, MD Amer Zeidan, MBBS, MPH
Physicians: maximum of 2.0 AMA PRA Category 1 Credits Released: January 13, 2022 Expired: January 12, 2023
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AbbVie Inc.
Gamida Cell Ltd.
Geron Corporation
Gilead Sciences, Inc.
Karyopharm Therapeutics Inc.
Takeda Pharmaceuticals U.S.A., Inc.: Takeda Oncology Company

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings